71 FR 37 pgs. 9458-9466 - Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B; Correcting Amendment
Type: RULEVolume: 71Number: 37Pages: 9458 - 9466
Docket number: [CMS-1502-F2 and CMS-1325-F]
FR document: [FR Doc. 06-1711 Filed 2-23-06; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Centers for Medicare Medicaid Services
Official PDF Version: PDF Version
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare Medicaid Services
42 CFR Parts 405, 410, 411, 413, 414, 424 and 426
[CMS-1502-F2 and CMS-1325-F]
RIN 0938-AN84 and 098-AN58
Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B; Correcting Amendment
AGENCY:
Centers for Medicare Medicaid Services (CMS), HHS.
ACTION:
Correcting amendment to final rule with comment.
SUMMARY:
In the November 21, 2005 Federal Register (70 FR 70116), we published a final rule with comment period entitled "Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B." This correcting amendment corrects technical errors in the November 21, 2005 publication.
EFFECTIVE DATE:
This correcting amendment is effective January 1, 2006.
FOR FURTHER INFORMATION CONTACT:
Diane Milstead, (410) 786-3355.
SUPPLEMENTARY INFORMATION:
I. Background
FR Doc. 05-22160, entitled "Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B" and appearing in the Federal Register on November 21, 2005 (70 FR 70116), addressed Medicare Part B payment policy, including the physician fee schedule, that is applicable for calendar year (CY) 2006; and finalized certain provisions of the interim final rule to implement the Competitive Acquisition Program (CAP) for Part B Drugs.
It also revised Medicare Part B payment and related policies regarding: Physician work, practice expense and malpractice relative value units (RVUs); Medicare telehealth services; multiple diagnostic imaging procedures; covered outpatient drugs and biologicals; supplemental payments to Federally Qualified Health Centers (FQHCs); renal dialysis services; coverage for glaucoma screening services; National Coverage Decision (NCD) timeframes; and physician referrals for nuclear medicine services and supplies to health care entities with which physicians have financial relationships.
In addition, the rule finalized the interim RVUs for CY 2005 and issued interim RVUs for new and revised procedure codes for CY 2006. This rule also updated the codes subject to the physician self-referral prohibition and discussed payment policies relating to teaching anesthesia services, therapy caps, private contracts and opt-out, and chiropractic and oncology demonstrations.
We have identified a number of technical errors in that final rule with comment period.
II. Summary of Errors
We are identifying and correcting errors made to certain parts of the preamble, regulations text and addenda of the November 21, 2005 final rule with comment (70 FR 70116). In addition, addendum B, C, D, E and F are revised under this correcting amendment, although these addenda will not appear in the Code of Federal Regulations.
A. Summary of Preamble Errors
In the preamble text, there were a number of errors and omissions beginning on pages 70150 through 70335.
1. On page 70150, in the first column, in the last paragraph under Section m. (Additional PE Issues Raised by Commenters), in the second sentence, the number of the CPT code referenced is incorrect.
2. On page 70155, in the center column, the last sentence of the second paragraph under the discussion titled, "3. Cardiac Catheritization and Angioplasty Exception," there was an error in one of the code ranges referenced.
3. On page 70263, in the third column; in last paragraph, the reference to Table 26 is incorrect.
4. On page 70263, Table 26 was numbered incorrectly.
5. On page 70274, in the first column; in the second paragraph language concerning the specific deleted practice expense items was inadvertently omitted.
6. On page 70282, in the second column; from the top of the column, lines 8 through 11, the sentence, "We are assigning a status indicator of N for these services because they are nonvcovered under Medicare." reflects an incorrect status indicator and will be revised.
7. On page 70282, in the third column; we inadvertently omitted a paragraph before section F. (Establishment of Interim PE RVUs for New and Revised Physician's Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006).
8. On page 70296, in the second column; in the last paragraph, in line 6, we incorrectly used the term "PFS", and that term will be replaced.
9. On page 70302, in Table 35, the figures for Annual Actual Expenditures and the Cumulative Actual Expenditures, for the period of 1/1/03-12/31/03, are incorrect and will be revised.
10. On page 70316, the first column, the percentage adjustment referenced in the third complete sentence is incorrect and will be revised.
11. On page 70320, the second footnote to Table 49 has incorrectly listed the numerical scaler. This footnote will be corrected.
These corrections are reflected in Section III.A of this correcting amendment.
B. Summary of Regulations Text Errors
In the regulation text, there were technical errors and omissions in § 405.2469, § 414.190, § 414.904, § 414.906, and § 426.340.
1. On page 70329, in the third column, under § 405.2469, paragraph (a)(1) does not reflect the correct format for amendatory language. Paragraph (a)(1) will be restructured.
2. On page 70331, in the third column, the reference to § 414.190 is incorrect.
3. On page 70332, in the third column, the title (Basis for payment.) for § 414.904 is incorrect.
4. On page 70333, in the first column, under § 414.906, we inadvertently omitted a change to bring the regulations text into conformity with our policy on updating CAP drug prices, as described in the interim final rule with comment period published July 6, 2005.
5. On page 70335, in the first column, under § 426.340, the statutory references in paragraphs (e)(2)(ii) and (f)(2)(ii) are incorrect.
The corrections are reflected in section III.B. of this correcting amendment.
C. Summary of Addendum B, C, D, E and F Errors
1. In Addendum B, pages 70337 through 70463, we are making the following corrections:
a. We assigned incorrect RVUs to the following Physicians' CPT or HCPCS codes:
50000:
i. 52648;
60000:
ii. 61630, 61635;
80000:
iii. 88385-26, 88385-TC, 88385, 88386-26, 88386-TC, and 88386;
90000:
iv. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 90775, 92626, 92627, 93514, 96401, 96402, 96405, 96406, 96409, 96411, 96413, 96415, 96416, 96417, 96420, 96440, 96450, 96521, 96522, 96542, 97606, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336, and 99337.
b. We assigned an incorrect global period for CPT code 92627.
c. We assigned incorrect status indicators to the following CPT or codes 0141T, 0142T, 0143T, 88385-26, 88385-TC, 88385, 88386-26, 88386-TC, 88386, 96523, 98960, 98961, 98962 and 99340.
d. The following HCPCS codes were inadvertently included: G9041, G9042, G9043 and G9044. These numbers should not have been included because they were not in effect.
e. HCPCS code G0332 was inadvertently omitted from the addendum.
f. The first footnote to addendum B should be corrected to read "1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply."
These corrections are reflected in Sections III.C.1. and 2. of this correcting amendment.
2. In Addendum C, pages 70463 through 70466, we are making the following corrections:
a. We assigned incorrect RVUs to the following CPT or alphanumeric HCPCS number for service codes:
60000:
i. 61630 and 61635.
80000:
ii. 88385-26 and 88386-26.
90000:
iii. 90760, 90761, 90765, 90766, 90767, 90768, 90772, 90773, 90774, 90775, 92626, 92627, 96401, 96402, 96409, 96411, 96413, 96415, 96416, 96417, 96450, 96521, 96522, 96523, 96542, 99300, 99324, 99325, 99326, 99327, 99328, 99334, 99335, 99336 and 99337.
b. We assigned incorrect status indicators to the following CPT codes 88385-26, 88386-26, 98960, 98961, 98962 and 99340.
These corrections are reflected in Section III.C.3 of this correcting amendment.
3. In Addendum D, pages 70466 through 70467, we are correcting the locality name "Kansas*" to read "Kansas".
These corrections are reflected in Section III.C.4 of this correcting amendment.
4. In Addendum E, pages 70468 through 70469, we are correcting the locality name "Kansas*" to read "Kansas".
These corrections are reflected in Section III.C.5 of this correcting amendment.
5. In Addendum F, pages 70469 through 70471, we are correcting this Addendum by replacing this Addendum in its entirety to address two errors. First, we inadvertently left a discontinued HCPCS code, J1750, on Addendum F. This code was replaced by J1751 and J1752 which are found on Addendum G "Revised New Drugs for CAP Bidding for 2006". Second, we included a new HCPCS code, J7318, which we understood would replace HCPCS codes J7317 and J7320. HCPCS J7318 was not issued and HCPCS codes J7317 J3120 were retained. We have reweighted and corrected Addendum F to reflect these changes.
These corrections are reflected in Section III.C.6 of this correcting amendment.
III. Correction of Errors
In FR Doc. 05-22160, entitled "Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B," which appeared in the Federal Register on November 21, 2005 (70 FR 70116), make the following corrections:
A. Correction of Preamble Errors
1. On page 70150, in the first column; in the last paragraph under Section m. (Additional PE Issues Raised by Commenters), in the second sentence, the number "99755" is corrected to read "97755".
2. On page 70155, in the center column; the last sentence of the second paragraph under the discussion titled, "3. Cardiac Catheterization and Angioplasty Exception," the number "93617" is corrected to read "93618".
3. On page 70263, in the third column; in the last paragraph, the phrase "Table 26" is corrected to read "Table 26A".
4. On page 70263, the table heading "Table 26.-Example of Payments" is corrected to read "Table 26A.-Example of Payments".
5. On page 70274, in the first column; in the second paragraph, the paragraph is corrected by adding a new sentence at the end of the paragraph to read as follows: "Because payment for the supplies and equipment for both of these procedures is provided under a separate DMERC policy, we have deleted the following practice expense items from these codes: Supplies deleted include dressings, both Adaptic and microporous, the drainage canister, and the sharp debridement kit-which was identified as not being needed for the typical scenario; and, the vacuum pump was deleted from the equipment."
6. On page 70282, in the second column; lines 8 through 11, the sentence, "We are assigning a status indicator of N for these services because they are noncovered under Medicare." is corrected to read, "We are assigning a status indicator of B for these services because payment for these services is bundled into payment for other Medicare services."
7. On page 70282, in the third column; we are adding a new paragraph before section F. (Establishment of Interim PE RVUs for New and Revised Physician's Current Procedural Terminology (CPT) Codes and New Healthcare Common Procedure Coding System (HCPCS) Codes for 2006). The new paragraph reads as follows: "CPT code 99339 Individual physician supervision of patient (patient not present) in home, domiciliary or rest home (e.g., assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment care decisions with health care professional(s), family member(s), surrogate decision maker(s) (e.g., legal guardian) and/or key caregiver(s) involved in patient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 15-29 minutes.
CPT code 99340 Individual physician supervision of patient (patient not present) in home, domiciliary or rest home (e.g., assisted living facility) requiring complex and multidisciplinary care modalities involving regular physician development and/or revision of care plans, review of subsequent reports of patient status, review of related laboratory and other studies, communication (including telephone calls) for purposes of assessment care decisions with health care professional(s), family member(s), surrogate decision maker(s) (e.g., legal guardian) and/or key caregiver(s) involved inpatient's care, integration of new information into the medical treatment plan and/or adjustment of medical therapy, within a calendar month; 30 minutes or more. We are assigning a status indicator of B for these codes because payment for these services is bundled into payment for other services."
8. On page 70296, in the second column; in the last paragraph, in line 6, the term "PFS" is corrected to read "Code List".
9. On page 70302, in Table 35; in the third column titled "Annual Actual Expenditures", in line 10 (1/1/03-12/31/03) of that column, "76.8" is corrected to read "78.2"; and in the fifth column titled "Cumulative Actual Expenditures", in line 10 (1/1/03-12/31/03) of that column, "460.6" is corrected to read "462.0".
10. On page 70316, in the first column; in the third complete sentence, the figure "-0.6" is corrected to read "-0.15".
11. On page 70320, in the second footnote to Table 49, the figure "0.9984" is corrected to read "0.9985".
B. Correction of Regulation Text Errors
List of Subjects
42 CFR Part 405
Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medical devices, Medicare, Reporting and recordkeeping requirements, Rural areas, X-rays.
42 CFR Part 414
Administrative practice and procedure, Health facilities, Health professions, Kidney diseases, Medicare, Reporting and recordkeeping requirements.
42 CFR Part 426
Administrative practice and procedure, Medicare, Reporting and recordkeeping requirements.
Given the errors summarized in section II.B. of this correcting amendment, we are making the following correcting amendments to 42 CFR parts 405, 414, and 426:
PART 405-FEDERAL HEALTH INSURANCE FOR THE AGED AND DISABLED
1. The authority citation for part 405 continues to read as follows:
Authority:
Secs. 1102, 1861, 1862(a), 1871, 1874, 1881, and 1886(k) of the Social Security Act (42 U.S.C. 1302, 1395x, 1395y(a), 1395hh, 1395kk, 1395rr, and 1395ww(k)), and sec. 353 of the Public Health Service Act (42 U.S.C. 263a).
2. Section 405.2469 is amended by revising paragraph (a)(1) to read as follows:
§ 405.2469 Federally Qualified Health Centers supplemental payments.
(a) Calculation of supplemental payment. (1) The supplemental payment for Federally Qualified Health Center covered services provided to Medicare patients enrolled in Medicare Advantage plans is based on the difference between-
(i) Payments received by the center from the Medicare Advantage plan as determined on a per visit basis; and
(ii) The Federally Qualified Health Center's all-inclusive cost-based per visit rate as set forth in this subpart, less any amount the FQHC may charge as described in section 1857(e)(3)(B) of the Act.
PART 414-PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES
3. The authority citation for part 414 continues to read as follows:
Authority:
Secs. 1102, 1871, and 1881(b)(1) of the Social Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(1)).
4. Section 414.906 is amended by revising paragraph (c)(1) introductory text to read as follows:
§ 414.906 Competitive acquisition program as the basis of payment.
(c) Computation of payment amount. (1) Except as specified in paragraph (c)(2) of this section, payment for CAP drugs is based on bids submitted, as a result of the bidding process as described in § 414.910. Based on these bids, a single payment amount for each CAP drug in the competitive acquisition area is determined on the basis of the bids submitted and accepted and updated from the bidding period to the payment year. This single payment amount is then updated on an annual basis based on the approved CAP vendor's reasonable net acquisition costs for that category as determined by CMS, based, in part, on information disclosed to CMS and limited by the weighted payment amount established under section 1847A of the Act across all drugs for which a composite bid is required in the category, and limited by the payment amount established under section 1847A of the Act for each other drug for which the approved CAP vendor submits a bid in accordance with § 414.910. Adjustment to the payment amounts may be made more often than annually, but no more often than quarterly, in any of the following cases:
PART 426-REVIEW OF NATIONAL COVERAGE DETERMINATIONS AND LOCAL COVERAGE DETERMINATIONS
5. The authority citation for part 426 continues to read as follows:
Authority:
Secs. 1102 and 1871 of the Social Security Act (42 U.S.C. 1302 and 1395hh).
6. Section 426.340 is amended by revising paragraphs (e)(2)(ii) and (f)(2)(ii) to read as follows:
§ 426.340 Procedures for review of new evidence.
(e) * * *
(2) * * *
(ii) For NCDs, in compliance with the timeframes specified in section 1862(1) of the Act, by which CMS completes the reconsideration.
(f) * * *
(2) * * *
(ii) For NCDs, the reconsideration timeframe specified by the Board, in compliance with section 1862(l) of the Act.
C. Correction of Addendum Errors
Given the errors summarized in Section II.C of this correcting amendment, we are making the following corrections to Addendum B, C, D, E, and F. These addenda will not appear in the Code of Federal Regulations.
1. On pages 70337 through 70463, the following entries to Addendum B are corrected to read as follows:
| CPT 1 /HCPCS 2 | Mod | Status | Description | Physician work RVUs 3 | Nonfacility PE RVUs | Facility PE RVUs | Malpractice RVUs | Nonfacility total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 0141T | I | Perq islet transplant | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 0142T | I | Open islet transplant | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 0143T | I | Laparoscopic islet transplant | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 52648 | A | Laser surgery of prostate | 11.19 | 74.15 | 4.80 | 0.79 | 86.07 | 16.78 | 090 | |
| 61630 | N | Intracranial angioplasty | +21.08 | NA | 12.53 | 2.01 | NA | 35.62 | 090 | |
| 61635 | N | Intracran angioplasty w/stent | +23.08 | NA | 13.58 | 2.20 | NA | 38.86 | 090 | |
| 88385 | 26 | A | Eval molecul probes, 51-250 | 1.50 | 0.65 | NA | 0.06 | 2.21 | NA | XXX |
| 88385 | TC | A | Eval molecul probes, 51-250 | 0.00 | 6.45 | NA | 0.06 | 6.51 | NA | XXX |
| 88385 | A | Eval molecul probes, 51-250 | 1.50 | 7.10 | NA | 0.12 | 8.72 | NA | XXX | |
| 88386 | 26 | A | Eval molecul probes, 251-500 | 1.88 | 0.82 | NA | 0.08 | 2.78 | NA | XXX |
| 88386 | TC | A | Eval molecul probes, 251-500 | 0.00 | 6.23 | NA | 0.08 | 6.31 | NA | XXX |
| 88386 | A | Eval molecul probes, 251-500 | 1.88 | 7.05 | NA | 0.16 | 9.09 | NA | XXX | |
| 90760 | A | Hydration iv infusion init | 0.17 | 1.43 | NA | 0.07 | 1.67 | NA | XXX | |
| 90761 | A | Hydrate iv infusion, add-on | 0.09 | 0.40 | NA | 0.04 | 0.53 | NA | ZZZ | |
| 90765 | A | Ther/proph/diag iv inf, init | 0.2 | 11.76 | NA | 0.07 | 2.04 | NA | XXX | |
| 90766 | A | Ther/proph/dg iv inf, add-on | 0.18 | 0.46 | NA | 0.04 | 0.68 | NA | ZZZ | |
| 90767 | A | Tx/proph/dg addl seq iv inf | 0.19 | 0.89 | NA | 0.04 | 1.12 | NA | ZZZ | |
| 90768 | A | Ther/diag concurrent inf | 0.17 | 0.44 | NA | 0.04 | 0.65 | NA | ZZZ | |
| 90772 | A | Ther/proph/diag inj, sc/im | 0.17 | 0.31 | NA | 0.01 | 0.49 | NA | XXX | |
| 90773 | A | Ther/proph/diag inj, ia | 0.17 | 0.31 | NA | 0.02 | 0.50 | NA | XXX | |
| 90774 | A | Ther/proph/diag inj, iv push | 0.18 | 1.30 | NA | 0.04 | 1.52 | NA | XXX | |
| 90775 | A | Ther/proph/diag inj add-on | 0.10 | 0.57 | NA | 0.04 | 0.71 | NA | ZZZ | |
| 92626 | A | Eval aud status rehab | 0.00 | 2.20 | NA | 0.06 | 2.26 | NA | XXX | |
| 92627 | A | Evallaud status rehab add-on | 0.00 | 0.55 | NA | .02 | 0.57 | NA | ZZZ | |
| 93514 | C | Left heart catheterization | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 000 | |
| 96401 | A | Chemo, anti-neopl, sq/im | 0.2 | 11.17 | NA | 0.01 | 1.39 | NA | XXX | |
| 96402 | A | Chemo hormon antineopl sq/im | 0.19 | 1.01 | NA | 0.01 | 1.21 | NA | XXX | |
| 96405 | A | Chemo intralesional, up to 7 | 0.52 | 2.44 | 0.24 | 0.03 | 2.99 | 0.79 | 000 | |
| 96406 | A | Chemo intralesional over 7 | 0.80 | 3.02 | 0.29 | 0.03 | 3.85 | 1.12 | 000 | |
| 96409 | A | Chemo, iv push, sngl drug | 0.24 | 2.93 | NA | 0.06 | 3.23 | NA | XXX | |
| 96411 | A | Chemo, iv push, addl drug | 0.20 | 1.61 | NA | 0.06 | 1.87 | NA | ZZZ | |
| 96413 | A | Chemo, iv infusion, 1 hr | 0.28 | 4.20 | NA | 0.08 | 4.56 | NA | XXX | |
| 96415 | A | Chemo, iv infusion, addl hr | 0.19 | 0.77 | NA | 0.07 | 1.03 | NA | ZZZ | |
| 96416 | A | Chemo prolong infuse w/pump | 0.21 | 4.61 | NA | 0.08 | 4.90 | NA | XXX | |
| 96417 | A | Chemo iv infuse each addl seq | 0.2 | 11.95 | NA | 0.07 | 2.23 | NA | ZZZ | |
| 96420 | A | Chemo, ia, push technique | 0.17 | 2.67 | NA | 0.08 | 2.92 | NA | XXX | |
| 96440 | A | Chemotherapy, intracavitary | 2.37 | 8.15 | 1.23 | 0.17 | 10.693.77 | 000 | ||
| 96450 | A | Chemotherapy, into CNS | 1.53 | 6.97 | 1.29 | 0.09 | 8.59 | 2.91 | 000 | |
| 96521 | A | Refill/maint, portable pump | 0.21 | 3.77 | NA | 0.06 | 4.04 | NA | XXX | |
| 96522 | A | Refill/maint pump/resvr syst | 0.21 | 2.65 | NA | 0.06 | 2.92 | NA | XXX | |
| 96523 | A | Irrig drug delivery device | 0.04 | 0.69 | NA | 0.01 | 0.74 | NA | XXX | |
| 96542 | A | Chemotherapy injection | 0.75 | 4.26 | 0.66 | 0.07 | 5.08 | 1.48 | XXX | |
| 97606 | A | Neg press wound tx, 50 cm | 0.60 | 0.35 | 0.24 | 0.03 | 0.98 | 0.87 | XXX | |
| CPT 1 /HCPCS 2 | Mod | Status | Description | Physician work RVUs 3 | Nonfacility PE RVUs | Facility PE RVUs | Malpractice RVUs | Nonfacility total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 98960 | B | Self-mgmt educ train, 1 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 98961 | B | Self-mgmt educ/train, 2-4 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 98962 | B | Self-mgmt educ/train, 5-8 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 99300 | A | lc, infant pbw 2501-5000 gm | 2.40 | NA | 0.84 | 0.15 | NA | 3.35 | XXX | |
| 99324 | A | Domicil/r-home visit new pat | 1.01 | 0.49 | NA | 0.05 | 1.55 | NA | XXX | |
| 99325 | A | Domicil/r-home visit new pat | 1.52 | 0.68 | NA | 0.07 | 2.27 | NA | XXX | |
| 99326 | A | Domicil/r-home visit new pat | 2.27 | 0.92 | NA | 0.10 | 3.29 | NA | XXX | |
| 99327 | A | Domicil/r-home visit new pat | 3.03 | 1.17 | NA | 0.13 | 4.33 | NA | XXX | |
| 99328 | A | Domicil/r-home visit new pat | 3.78 | 1.42 | NA | 0.16 | 5.36 | NA | XXX | |
| 99334 | A | Domicil/r-home visit est pat | 0.76 | 0.40 | NA | 0.04 | 1.20 | NA | XXX | |
| 99335 | A | Domicil/r-home visit est pat | 1.26 | 0.58 | NA | 0.06 | 1.90 | NA | XXX | |
| 99336 | A | Domicil/r-home visit est pat | 2.02 | 0.82 | NA | 0.09 | 2.93 | NA | XXX | |
| 99337 | A | Domicil/r-home visit est pat | 3.03 | 1.15 | NA | 0.13 | 4.31 | NA | XXX | |
| 99340 | B | Domicil/r-home care supervis | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| G0332 | A | Preadmin IV immunoglobulin | 0.00 | 1.91 | NA | 0.00 | 1.91 | NA | XXX | |
| 1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. | ||||||||||
| 2 Copyright 2005 American Dental Association. All Rights Reserved. | ||||||||||
| 3 Indicates RVUs are not used for Medicare payment. | ||||||||||
2. On page 70463, the following entries to Addendum B, G9041, G9042, G9043, and G9044 are removed.
| CPT1 /HCPCS2 | Mod | Status | Description | Physician work RVUs3 | Nonfacility PE RVUs | Facility PE RVUs | Malpractice RVUs | Nonfacility total | Facility total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| G9041 | X | Low vision rehab occupationa | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| G9042 | X | Low vision rehab orient/mobi | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| G9043 | X | Low vision lowvision therapy | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| G9044 | X | Low vision rehabilate teache | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. | ||||||||||
| 2 Copyright 2005 American Dental Association. All Rights Reserved. | ||||||||||
| 3 +Indicates RVUs are not used for Medicare payment. | ||||||||||
3. On pages 70463 through 70466, the following entries to Addendum C are corrected to read as follows:
| CPT1 / HCPCS2 | Mod | Status | Description | Physician work RVUs3 | Nonfacility PE RVUs | Facility PE RVUs | Malpractice RVUs | Nonfacility Total | Facility Total | Global |
|---|---|---|---|---|---|---|---|---|---|---|
| 61630 | N | Intracranial angioplasty | +21.08 | NA | 12.53 | 2.01 | NA | 35.62 | 090 | |
| 61635 | N | Intracran angioplasty w/stent | +23.08 | NA | 13.58 | 2.20 | NA | 30.66 | 090 | |
| 88385 | 26 | A | Eval Molecul probes, 51-250 | 1.50 | 0.65 | NA | 0.06 | 2.21 | NA | XXX |
| 88386 | 26 | A | Eval Molecul probes, 251-500 | 1.88 | 0.82 | NA | 0.08 | 2.78 | NA | XXX |
| 90760 | A | Hydration iv infusion, init | 0.17 | 1.43 | NA | 0.07 | 1.67 | NA | XXX | |
| 90761 | A | Hydrate iv infusion, add-on | 0.09 | 0.40 | NA | 0.04 | 0.53 | NA | ZZZ | |
| 90765 | A | Ther/proph/diag iv inf, init | 0.21 | 1.76 | NA | 0.07 | 2.04 | NA | XXX | |
| 90766 | A | Ther/proph/dg iv inf, add-on | 0.18 | 0.46 | NA | 0.04 | 0.68 | NA | ZZZ | |
| 90767 | A | Tx/proph/dg addl seq iv inf | 0.19 | 0.89 | NA | 0.04 | 1.12 | NA | ZZZ | |
| 90768 | A | Ther/diag concurrent inf | 0.17 | 0.44 | NA | 0.04 | 0.65 | NA | ZZZ | |
| 90772 | A | Ther/proph/diag inj, sc/im | 0.17 | 0.31 | NA | 0.01 | 0.49 | NA | XXX | |
| 90773 | A | Ther/proph/diag inj, ia | 0.17 | 0.31 | NA | 0.02 | 0.50 | NA | XXX | |
| 90774 | A | Ther/proph/diag inj, iv push | 0.18 | 1.30 | NA | 0.04 | 1.52 | NA | XXX | |
| 90775 | A | Ther/proph/diag inj add-on | 0.10 | 0.57 | NA | 0.04 | 0.71 | NA | ZZZ | |
| 92626 | A | Eval aud status rehab | 0.00 | 2.20 | NA | 0.06 | 2.26 | NA | XXX | |
| 92627 | A | Evalaud status rehab add-on | 0.00 | 0.55 | NA | 0.02 | 0.57 | NA | ZZZ | |
| 96401 | A | Chemo, anti-neopl, sq/im | 0.21 | 1.17 | NA | 0.01 | 1.39 | NA | XXX | |
| 96402 | A | Chemo hormone antineopl sq/im | 0.19 | 1.01 | NA | 0.01 | 1.21 | NA | XXX | |
| 96409 | A | Chemo, iv push, sngl drug | 0.24 | 2.93 | NA | 0.06 | 3.23 | NA | XXX | |
| 96411 | A | Chemo, iv push, addl drug | 0.20 | 1.61 | NA | 0.06 | 1.87 | NA | ZZZ | |
| 96413 | A | Chemo, iv infusion, 1 hr | 0.28 | 4.20 | NA | 0.08 | 4.56 | NA | XXX | |
| 96415 | A | Chemo, iv infusion, addl hr | 0.19 | 0.77 | NA | 0.07 | 1.03 | NA | ZZZ | |
| 96416 | A | Chemo prolong infuse w/pump | 0.21 | 4.61 | NA | 0.08 | 4.90 | NA | XXX | |
| 96417 | A | Chemo iv infuse each addl seq | 0.21 | 1.95 | NA | 0.07 | 2.23 | NA | ZZZ | |
| 96450 | A | Chemotherapy, into CNS | 1.53 | 6.97 | 1.29 | 0.09 | 8.59 | 2.91 | 000 | |
| 96521 | A | Refill/maint, portable pump | 0.21 | 3.77 | NA | 0.06 | 4.04 | NA | XXX | |
| 96522 | A | Refil/maint pump/resvr syst | 0.21 | 2.65 | NA | 0.06 | 2.92 | NA | XXX | |
| 96523 | A | Irrig drug delivery device | 0.04 | 0.69 | NA | 0.01 | 0.74 | NA | XXX | |
| 96542 | A | Chemotherapy injection | 0.75 | 4.26 | 0.66 | 0.07 | 5.08 | 1.48 | XXX | |
| 98960 | B | Self-mgmt educ train, 1 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 98961 | B | Self-mgmt educ/train, 2-4 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 98962 | B | Self-mgmt educ/train 5-8 pt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 99300 | A | Ic, infant pbw 2501-5000 gm | 2.40 | NA | 0.84 | 0.15 | NA | 3.35 | XXX | |
| 99324 | A | Domicil/r-home visit new pat | 1.01 | 0.49 | NA | 0.05 | 1.55 | NA | XXX | |
| 99325 | A | Domicil/r-home visit new pat | 1.52 | 0.68 | NA | 0.07 | 2.27 | NA | XXX | |
| 99326 | A | Domicil/r-home visit new pat | 2.27 | 0.92 | NA | 0.10 | 3.29 | NA | XXX | |
| 99327 | A | Domicil/r-home visit new pat | 3.03 | 1.17 | NA | 0.13 | 4.33 | NA | XXX | |
| 99328 | A | Domicil/r-home visit new pat | 3.78 | 1.42 | NA | 0.16 | 5.36 | NA | XXX | |
| 99334 | A | Domicil/r-home visit est pat | 0.76 | 0.40 | NA | 0.04 | 1.20 | NA | XXX | |
| 99335 | A | Domicil/r-home visit est pat | 1.26 | 0.58 | NA | 0.06 | 1.90 | NA | XXX | |
| 99336 | A | Domicil/r-home visit est pat | 2.02 | 0.82 | NA | 0.09 | 2.93 | NA | XXX | |
| 99337 | A | Domicil/r-home visit est pat | 3.03 | 1.15 | NA | 0.13 | 4.31 | NA | XXX | |
| 99340 | B | Domicil/r-home care supervis | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | XXX | |
| 1 CPT codes and descriptions only. Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply. | ||||||||||
| 2 Copyright 2005 American Dental Association. All Rights Reserved. | ||||||||||
| 3 +Indicates RVUs are not used for Medicare payment. | ||||||||||
4. On page 70467, in Addendum D, in the 11th entry, in the third column, the locality "Kansas*" is corrected to read "Kansas" as follows:
| Carrier | Locality | Locality name | Work GPCI | PE GPCI | MP GPCI |
|---|---|---|---|---|---|
| 00650 | 00 | Kansas | 1.000 | 0.878 | 0.721 |
5. On page 70469, in Addendum E, in the fourth entry, in the third column, the locality "Kansas*" is corrected to read "Kansas" as follows:
| Carrier | Locality | Locality name | 2006 GAF |
|---|---|---|---|
| 00650 | 00 | Kansas | 0.0936 |
6. On pages 70469 through 70471, Addendum F, in its entirety, is corrected to read as follows:
| HCPCS | Long description | Weight |
|---|---|---|
| J0150 | Injection, adenosine for therapeutic use, 6 mg | 0.00070000 |
| J0152 | Injection, adenosine for diagnostic use, 30 mg | 0.00459478 |
| J0170 | Injection, adrenalin, epinephrine, 1 ml ampule | 0.00007897 |
| J0207 | Injection, amifostine, 500 mg | 0.00016099 |
| J0215 | Injection, alefacept, 0.5 mg | 0.00083383 |
| J0280 | Injection, aminophyllin, 250 mg | 0.00082088 |
| J0290 | Injection, ampicillin sodium, 500 mg | 0.00012657 |
| J0475 | Injection, baclofen, 10 mg | 0.00024643 |
| J0540 | Injection, penicillin g benzathine and penicillin g procaine, 1,200,000 units | 0.00007209 |
| J0550 | Injection, penicillin g benzathine and penicillin g procaine, 2,400,000 units | 0.00001831 |
| J0570 | Injection, penicillin g benzathine, 1,200,000 units | 0.00004605 |
| J0585 | Botulinum toxin type A, per unit | 0.03743206 |
| J0587 | Botulinum toxin type B, per 100 units | 0.00150704 |
| J0600 | Injection, edetate calcium disodium, 1000 mg | 0.00004459 |
| J0637 | Injection, caspofungin acetate, 5 mg | 0.00008483 |
| J0640 | Injection, leucovorin calcium, per 50 mg | 0.01064503 |
| J0670 | Injection, mepivacaine hydrochloride, per 10 ml | 0.00038398 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0.00042410 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0.00024846 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0.00668833 |
| J0698 | Injection, cefotaxime sodium, per gm | 0.00014878 |
| J0702 | Injection, betamethasone acetate betamethasone sodium phosphate, per 3 mg | 0.00287709 |
| J0704 | Injection, betamethasone sodium phosphate, per 4 mg | 0.00057059 |
| J0735 | Injection, clonidine hydrochloride, 1 mg | 0.00034149 |
| J0800 | Injection, corticotropin, 40 units | 0.00363945 |
| J0881 | Injection, darbepoetin alfa, 1 mcg (non-ESRD use) | 0.15953454 |
| J0885 | Injection, epoetin alpha, (for non ESRD use), per 1000 units | 0.25136609 |
| J0895 | Injection, deferoxamine mesylate, 500 mg | 0.00024448 |
| J1000 | Injection, depo-estradiol cypionate, 5 mg | 0.00021013 |
| J1020 | Injection, methylprednisolone acetate, 20 mg | 0.00127329 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0.00593138 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0.00527803 |
| J1051 | Injection, medroxyprogesterone acetate, 50 mg | 0.00006526 |
| J1094 | Injection, dexamethasone acetate, 1 mg | 0.00351268 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0.05492057 |
| J1190 | Injection, dexrazoxane hydrochloride, per 250 mg | 0.00002444 |
| J1200 | Injection, diphenhydramine hcl, 50 mg | 0.00216491 |
| J1212 | Injection, DMSO, dimethyl sulfoxide, 50%, 50 ml | 0.00008475 |
| J1245 | Injection, dipyridamole, per 10 mg | 0.00383178 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0.00053182 |
| J1260 | Injection, dolasetron mesylate, 10 mg | 0.01737101 |
| J1335 | Injection, ertapenem sodium, 500 mg | 0.00013263 |
| J1440 | Injection, filgrastim (G-CSF), 300 mcg | 0.00193572 |
| J1441 | Injection, filgrastim (G-CSF), 480 mcg | 0.00407388 |
| J1450 | Injection fluconazole, 200 mg | 0.00001609 |
| J1580 | Injection, garamycin, gentamicin, 80 mg | 0.00039937 |
| J1600 | Injection, gold sodium thiomalate, 50 mg | 0.00005613 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | 0.01483731 |
| J1631 | Injection, haloperidol decanoate, per 50 mg | 0.00020702 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0.06422737 |
| J1644 | Injection, heparin sodium, per 1000 units | 0.00354562 |
| J1645 | Injection, dalteparin sodium, per 2500 iu | 0.00011526 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0.00135618 |
| J1655 | Injection, tinzaparin sodium, 1000 iu | 0.00047170 |
| J1720 | Injection, hydrocortisone sodium succinate, 100 mg | 0.00013327 |
| J1745 | Injection infliximab, 10 mg | 0.02762721 |
| J1756 | Injection, iron sucrose, 1 mg | 0.01026994 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0.00330082 |
| J1940 | Injection, furosemide, 20 mg | 0.00065369 |
| J1956 | Injection, levofloxacin, 250 mg | 0.00008629 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0.00077528 |
| J2010 | Injection, lincomycin hcl, 300 mg | 0.00062461 |
| J2150 | Injection, mannitol, 25% in 50 ml | 0.00029211 |
| J2260 | Injection, milrinone lactate, 5 mg | 0.00004959 |
| J2300 | Injection, nalbuphine hydrochloride, per 10 mg | 0.00026341 |
| J2325 | Injection, nesiritide, 0.1 mg | 0.00027406 |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | 0.00195107 |
| J2354 | Injection, octreotide, non-depot subcutaneous or intravenous injection, 25 mcg | 0.00008412 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0.01373037 |
| J2430 | Injection, pamidronate disodium, per 30 mg | 0.00156790 |
| J2505 | Injection, pegfilgrastim, 6 mg | 0.00065114 |
| J2550 | Injection, promethazine hcl, 50 mg | 0.00068681 |
| J2680 | Injection, fluphenazine decanoate, 25 mg | 0.00015113 |
| J2765 | Injection, metoclopramide hCL, 10 mg | 0.00011134 |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | 0.00088550 |
| J2820 | Injection, sargramostim (GM-CSF), 50 mcg | 0.00217910 |
| J2912 | Injection, sodium chloride, 0.9%, per 2 ml | 0.00680009 |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0.00061134 |
| J2920 | Injection, methylprednisolone sodium succinate, 40 mg | 0.00031230 |
| J2930 | Injection, methylprednisolone sodium succinate, 125 mg | 0.00077199 |
| J2997 | Injection, alteplase recombinant, 1 mg | 0.00012239 |
| J3260 | Injection, tobramycin sulfate, 80 mg | 0.00018292 |
| J3301 | Injection, triamcinolone acetonide, per 10 mg | 0.02166537 |
| J3302 | Injection, triamcinolone diacetate, per 5 mg | 0.00173214 |
| J3303 | Injection, triamcinolone hexacetonide, per 5 mg | 0.00094603 |
| J3315 | Injection, triptorelin pamoate, 3.75 mg | 0.00000713 |
| J3370 | Injection, vancomycin hCL, 500 mg | 0.00084187 |
| J3396 | Injection, verteporfin, 0.1 mg | 0.05438624 |
| J3410 | Injection, hydroxyzine hCL, 25 mg | 0.00041004 |
| J3420 | Injection, vitamin B-12 cyanocobalamin, up to 1000 mcg | 0.01203050 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0.00108505 |
| J3480 | Injection, potassium chloride, per 2 meq | 0.00215709 |
| J3487 | Injection, zoledronic acid, 1 mg | 0.00336479 |
| J7030 | Infusion, normal saline solution, 1000 cc | 0.00102834 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0.00243166 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0.00049872 |
| J7050 | Infusion, normal saline solution, 250 cc | 0.00993344 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 0.00102860 |
| J7070 | Infusion, D5W, 1000 cc | 0.00015894 |
| J7120 | Ringers lactate infusion, 1000 cc | 0.00016980 |
| J7317 | Sodium hyaluronate, per 20 to 25 mg dose for intra-articular injection | 0.00191598 |
| J7320 | Hylan G-F 20, 16 mg, for intra articular injection | 0.00149854 |
| J9000 | Doxorubicin hCL, 10 mg | 0.00235846 |
| J9001 | Doxorubicin hydrochloride, all lipid formulations, 10 mg | 0.00032536 |
| J9031 | BCG (Intravesical) per instillation | 0.00049267 |
| J9040 | Bleomycin sulfate, 15 units | 0.00003728 |
| J9045 | Carboplatin, 50 mg | 0.00570096 |
| J9050 | Carmustine, 100 mg | 0.00000890 |
| J9060 | Cisplatin, powder or solution, per 10 mg | 0.00095393 |
| J9062 | Cisplatin, 50 mg | 0.00025430 |
| J9065 | Injection, cladribine, per 1 mg | 0.00008142 |
| J9070 | Cyclophosphamide, 100 mg | 0.00062691 |
| J9080 | Cyclophosphamide, 200 mg | 0.00004968 |
| J9090 | Cyclophosphamide, 500 mg | 0.00008125 |
| J9091 | Cyclophosphamide, 1.0 gram | 0.00005049 |
| J9092 | Cyclophosphamide, 2.0 gram | 0.00000530 |
| J9093 | Cyclophosphamide, lyophilized, 100 mg | 0.00092680 |
| J9094 | Cyclophosphamide, lyophilized, 200 mg | 0.00009190 |
| J9095 | Cyclophosphamide, lyophilized, 500 mg | 0.00017696 |
| J9096 | Cyclophosphamide, lyophilized, 1.0 gram | 0.00013977 |
| J9097 | Cyclophosphamide, lyophilized, 2.0 gram | 0.00001360 |
| J9098 | Cytarabine liposome, 10 mg | 0.00000817 |
| J9100 | Cytarabine, 100 mg | 0.00013010 |
| J9110 | Cytarabine, 500 mg | 0.00002076 |
| J9130 | Dacarbazine, 100 mg | 0.00009429 |
| J9140 | Dacarbazine, 200 mg | 0.00007024 |
| J9150 | Daunorubicin, 10 mg | 0.00000490 |
| J9170 | Docetaxel, 20 mg | 0.00257221 |
| J9178 | Injection, epirubicin hCL, 2 mg | 0.00121917 |
| J9181 | Etoposide, 10 mg | 0.00231466 |
| J9182 | Etoposide, 100 mg | 0.00053112 |
| J9185 | Fludarabine phosphate, 50 mg | 0.00030647 |
| J9190 | Fluorouracil, 500 mg | 0.00396193 |
| J9200 | Floxuridine, 500 mg | 0.00000409 |
| J9201 | Gemcitabine hCL, 200 mg | 0.00496182 |
| J9202 | Goserelin acetate implant, per 3.6 mg | 0.00288597 |
| J9206 | Irinotecan, 20 mg | 0.00319095 |
| J9208 | Ifosfamide, 1 gm | 0.00007892 |
| J9209 | Mesna, 200 mg | 0.00036868 |
| J9211 | Idarubicin hydrochloride, 5 mg | 0.00000318 |
| J9213 | Interferon, ALFA-2A, recombinant, 3 million units | 0.00008082 |
| J9214 | Interferon, ALFA-2B, recombinant, 1 million units | 0.00675198 |
| J9219 | Leuprolide acetate implant, 65 mg | 0.00006526 |
| J9245 | Injection, melphalan hydrochloride, 50 mg | 0.00000159 |
| J9250 | Methotrexate sodium, 5 mg | 0.00186700 |
| J9260 | Methotrexate sodium, 50 mg | 0.00051449 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 0.07318565 |
| J9265 | Paclitaxel, 30 mg | 0.00556692 |
| J9268 | Pentostatin, per 10 mg | 0.00000645 |
| J9280 | Mitomycin, 5 mg | 0.00004077 |
| J9290 | Mitomycin, 20 mg | 0.00003481 |
| J9291 | Mitomycin, 40 mg | 0.00006143 |
| J9293 | Injection, mitoxantrone hydrochloride, per 5 mg | 0.00025120 |
| J9310 | Rituximab, 100 mg | 0.00409565 |
| J9320 | Streptozocin, 1 gm | 0.00000673 |
| J9340 | Thiotepa, 15 mg | 0.00002452 |
| J9350 | Topotecan, 4 mg | 0.00018268 |
| J9355 | Trastuzumab, 10 mg | 0.00543348 |
| J9360 | Vinblastine sulfate, 1 mg | 0.00035813 |
| J9370 | Vincristine sulfate, 1 mg | 0.00019751 |
| J9375 | Vincristine sulfate, 2 mg | 0.00011515 |
| J9390 | Vinorelbine tartrate, per 10 mg | 0.00111035 |
| J9395 | Injection, fulvestrant, 25 mg | 0.00126670 |
| J9600 | Porfimer sodium, 75 mg | 0.00000030 |
| Q3025 | Injection, interferon BETA-1A, 11 mcg for intramuscular use | 0.00078263 |
IV. Waiver of Proposed Rulemaking and Delay in Effective Date
We ordinarily publish a notice of proposed rulemaking in the Federal Register to provide a period for public comment before the provisions of a rule take effect in accordance with section 553(b) of the Administrative Procedure Act (APA) (5 U.S.C. 553(b)). However, we can waive the notice and comment procedures if the Secretary finds, for good cause, that the notice and comment process is impracticable, unnecessary or contrary to the public interest, and incorporates a statement of the finding and the reasons therefore in the rule. We can also waive the 30-day delay in effective date under the APA (5 U.S.C. 553(d)) when there is good cause to do so and we publish in the rule an explanation of our good cause.
This correcting amendment addresses technical errors and omissions made in FR Doc. 05-22160, entitled "Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006 and Certain Provisions Related to the Competitive Acquisition Program of Outpatient Drugs and Biologicals Under Part B," which appeared in the Federal Register on November 21, 2005 (70 FR 70116) and was made effective January 1, 2006. The provisions of this final rule with comment period have been previously subjected to notice and comment procedures. These corrections are consistent with the discussion and text and do not make substantive changes to the CY 2006 published rule. As such, this correcting amendment is intended to ensure the CY 2006 final rule with comment accurately reflects the policy adopted. Therefore, we find that undertaking further notice and comment procedures to incorporate these corrections into the final rule with comment is unnecessary and contrary to the public interest.
For the same reasons, we are also waiving the 30-day delay in effective date for this correcting amendment. We believe that it is in the public interest to ensure that the CY 2006 final rule with comment accurately states our policy on physician fee schedule and other Part B payment policies, and provisions related to the competitive acquisition program of outpatient drugs and biologicals under Part B. Therefore, delaying the effective date of these corrections beyond the January 1, 2006 effective date of the final rule with comment period would be contrary to the public interest. In so doing, we find good cause to waive the 30-day delay in the effective date.
(Catalog of Federal Domestic Assistance Program No. 93.774, Medicare-Supplementary Medical Insurance Program)
Dated: February 7, 2006.
Ann C. Agnew,
Executive Secretary to the Department.
[FR Doc. 06-1711 Filed 2-23-06; 8:45 am]
BILLING CODE 4120-01-P